An observational study in Insomnia and Psychiatric Disorders, sponsored by Shanghai Mental Health Center. Recruiting at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Shanghai Mental Health Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.
Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 27th largest by planned enrollment of the 36 observational ones that give a count, is one of 28 that started in 2026, is one of 36 observational ones, reaches primary completion later than 44 of the 87 other live ones, and was the 171st registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:
Sichuan Academy of Medical Sciences · Sites in China
Ages 18–80
China Medical University, China · Sites in China
Ages 60+
Renmin Hospital of Wuhan University · Sites in China
Ages 18–79
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+
Huazhong University of Science and Technology · Sites in China
Ages 40–65 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 9 · Phase 4 13
First in 2006; this study’s year is marked. 28 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 121 is below the median of 138 across 321 observational studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 88 across the 162 interventional studies, 200 across the 36 observational. Of the 82 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 198 have an industry lead sponsor. The 10 most frequent:
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 95 are open to participants now.
Shanghai Mental Health Center has 6 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
29 of the studies in Sleep Initiation and Maintenance Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07738809Capital University of Physical Education and Sports, ChinaEffects of Exercise Intervention on Sleep Quality and Emotional Problems in College Students With Depressive Symptoms | 2026-11 |
| NCT07730762Xijing HospitalA Study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During Pregnancy | 2026-11-30 |
| NCT07340268Zan WangThe Effects of Transcranial Current Stimulation on Insomnia | 2026-11-30 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
Add all 29 to your calendar (.ics) → With an account.
Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effectiveness and safety of lemborexant (a new dual orexin receptor antagonist) in the treatment of patients with mental disorders complicated with insomnia. The subjects are patients aged 18 years and above, who meet the DSM-5 diagnostic criteria for mental disorders and have an Insomnia Severity Index (ISI) score ≥11. They will receive lemborexant treatment for 8 weeks, with follow-up to observe the improvement of insomnia symptoms and adverse events, so as to provide real-world evidence for the clinical optimization of treatment regimens for insomnia comorbid with psychiatric disorders.
Background: The incidence of insomnia in patients with psychiatric disorder is as high as 70%-80%. Traditional benzodiazepine receptor agonists have risks such as addiction and cognitive impairment. Lemborexant was approved for marketing in China in 2025, but its real-world data in the population with insomnia comorbid with psychiatric disorder is insufficient. Hypothesis: 8-week treatment with lemborexant can significantly improve insomnia symptoms in insomnia comorbid with psychiatric disorders, with good safety. Design: A multicenter, prospective, single-arm, observational study. It is planned to enroll 121 patients (with an expected dropout rate of 30%), who will receive 8-week treatment. Efficacy will be evaluated by scales such as ISI and VAS, and adverse events will be monitored.
Adults ≥18 years with any DSM-5-diagnosed mental disorder, ISI score ≥11, ≥7 hours available sleep time, ability to complete 2-month assessments/follow-up, voluntary informed consent, and clinical indication for lemborexant treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled patients receive lemborexant treatment, with a study cycle of 8 weeks (including a baseline assessment period ≤1 week and an 8-week treatment observation period)
Drug: Lemborexant tablets
Lemborexant Tablets (Dayvigo® tablets 5 mg): Oral administration, taken before bedtime. The initial dose is 5mg/day, which can be adjusted to 10mg/day (maximum dose: 10mg/day) based on clinical response and tolerability. For patients using benzodiazepine receptor agonists(BZRAs) at baseline, it is recommended to gradually reduce and discontinue BZRAs within the first 4 weeks.
Change in Insomnia Severity Index (ISI) Score from Baseline
Change in Insomnia Severity Index (ISI) Score from Baseline: Evaluated by the ISI scale (7 items, total score 0-28 points).
Time frame: Measurement time points: Baseline, Week 4 of treatment, Week 8 of treatment
ISI Treatment Response Rate
Proportion of patients with an ISI score decrease of ≥7 points from baseline.
Time frame: Measurement time points: Week 4 and Week 8 of treatment
ISI Remission Rate
Proportion of patients with an ISI score \<8 points.
Time frame: Measurement time points: Week 4 and Week 8 of treatment
Change in Sleep Satisfaction VAS Score
Including 3 dimensions (sleep onset efficiency, sleep maintenance, impact on daytime function) with 1-10 points for each dimension.
Time frame: Measurement time points: Baseline, Week 4 and Week 8 of treatment
Change in Epworth Sleepiness Scale (ESS) Score
Change in Epworth Sleepiness Scale (ESS) Score: Total score 0-24 points.
Time frame: Measurement time points: Baseline, Week 4 and Week 8 of treatment
Lemborexant Treatment Retention Rate
Lemborexant Treatment Retention Rate: Proportion of patients still using lemborexant at Week 4 and Week 8 of treatment;
Time frame: Week 4 and Week 8 of treatment
BZRAs Discontinuation Rate
Discontinuation rate of patients using BZRAs at baseline
Time frame: Measurement time points: Week 4 and Week 8 of treatment
BZRAs Dose Change
Change in diazepam-equivalent dose from baseline
Time frame: Measurement time points: Week 4 and Week 8 of treatment
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 7 months after the start.
Of 127 non-industry observational studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's planned 7 months is below that.
Counting every sponsor, half of 138 studies reached it within 18 months; a quarter within 4 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
Shanghai Mental Health Center →